General Terms & Conditions of Purchase Learn more about the conditions that govern purchases of products and services by companies within the BICO Group including terms of delivery, delay, IP, term and termination etc. The General Terms & Conditions

FRANKLIN LAKES, N.J. and SAN DIEGO (Jan. 23, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today

2025 2024 2023 2022 2021 2020 2019 2018 Documents Annual General Meeting 8 May 2025 → Notice AGM Nomination Committee proposals and reasoned statement Proxy form Notification of attendance and form for advance voting Auditor’s report in accordance with

In accordance with the decision by the Annual General Meeting 2025 when the most recent principles regarding the composition of the nomination committee were adopted, the Nomination Committee of BICO Group AB shall consist of four members appointed by the

Corporate Governance Report 2024 Corporate Governance Report 2023 Corporate Governance Report 2022 Corporate Governance Report 2021 Corporate Governance Report 2019/2020 Corporate Governance Report

Maria Rankka Board Chair More info Born 1975. Board Chair since 2025. Member of the Remuneration Committee and the Audit Committee.   Education and work experience:BA Political Science, Economics, and Business, Uppsala university and Stanford Executive

Maria Forss President and CEO More info Born 1972. CEO since 2023. Education and work experience: M.Sc. in Business Administration from Gothenburg School of Economics & Concordia University, Montreal, Canada. Executive Management Program at Stanford

BICO enables and automates the life science lab of the future – driving innovation, efficiency, and impact across the healthcare sector. Stay up to date with our financial reports, our strategy 2.0, and visit our investor newsroom. Q4 Report 2025 Read

All numbers on this page refers to Ginolis being classified as discontinued operations from the Q4 2023, Nanoscribe from Q4 2024 and Mattek and Visiokol from Q2 2025 with retroactive effect. * From Q1 2024, BICO has changed to functional reporting with

BICO enables and automates the life science lab of the future Download Q4 Report 2025 Solutions Discover our instruments, software and biomaterials for life science research. Applications Learn more about some of the key applications our products are used for